Evidence map›Paper›PMID 41176520›Full record

Observational studyProstate cancer and prostatic diseases2026

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.

Evan Y Yu, Hiroyoshi Suzuki, Christopher M Pieczonka, Geoffrey Gotto, Alberto Briganti, Murilo Luz, Declan Murphy, Ryan Malone, Joelle Hamilton, Jonathan E Chan and 14 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Evan Y YuFred Hutchinson Cancer Center and University of Washington, Seattle, WA, USA. evanyu@uw.edu.ORCID http://orcid.org/0000-0002-1510-8044
Hiroyoshi SuzukiToho University Sakura Medical Center, Chiba, Japan.
Christopher M PieczonkaAssociated Medical Professionals of NY, Syracuse, NY, USA.ORCID http://orcid.org/0000-0002-2531-7587
Geoffrey GottoUniversity of Calgary, Southern Alberta Institute of Urology, Calgary, AB, Canada.
Alberto BrigantiUrological Research Institute, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.
Murilo LuzHospital Erasto Gaertner, Curitiba, Brazil.ORCID http://orcid.org/0000-0002-0575-5635
Declan MurphyUniversity of Melbourne and Peter MacCallum Cancer Centre, Melbourne, Australia.ORCID http://orcid.org/0000-0002-7500-5899
Ryan MaloneFirst Urology, Jeffersonville, IN, USA.
Joelle HamiltonUrology Centers of Alabama, Homewood, AL, USA.
Jonathan E ChanDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Paul SieberKeystone Urology Specialists, Lancaster, PA, USA.
Robert W GivenUrology of Virginia, Virginia Beach, VA, USA.
Eva HellmisUrologicum Duisburg, Duisburg, Germany.
Thomas KretzUrologie-Heinsberg, Heinsberg, Germany.
Philipp SpiegelhalderUrologie Neandertal, Mettmann, Germany.
Antonio Gómez-CaamañoHospital Clínico Universitario, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0002-9773-4590
Yaovi Messan AmelaCentre Bourgogne, Hôpital Privé le Bois, Lille, France.
Xavier ArtignanCentre Hospitalier Privé Saint-Grégoire, Saint-Grégoire, France.
Hiroji UemuraYokohama City University Medical Center, Yokohama, Japan.
Naoki FujitaHirosaki University Graduate School of Medicine, Hirosaki, Japan.
Patrick AdorjanBayer Consumer Care AG, Basel, Switzerland.
Mercedeh GhadessiBayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Frank VerholenBayer Consumer Care AG, Basel, Switzerland.
Andrew J ArmstrongDuke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0001-7012-1754

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDAROL is an ongoing study of real-world safety and effectiveness of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). SUBJECTS/

methodsThis prespecified interim analysis included 550 patients with nmCRPC who completed ≥6 months of treatment with darolutamide 600 mg twice daily.

resultsDarolutamide showed consistent safety and effectiveness in DAROL vs ARAMIS. Most treatment-emergent adverse events were grade 1/2. Two-year overall survival and metastasis-free survival rates and prostate-specific antigen responses were similar to ARAMIS.

conclusionsThese findings indicate that darolutamide offers effectiveness and a favorable safety profile in the broad range of patients seen in clinical practice.

Indexed as

Prostatic Neoplasms, Castration-ResistantPyrazolesAgedAged, 80 and overHumansMaleMiddle AgedProstate-Specific AntigenTreatment OutcomedarolutamideProstate-Specific AntigenPyrazoles

Identifiers

PMID41176520
PMCPMC13472950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.